博腾股份(300363) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥773,997,978.15, representing a 37.52% increase year-over-year[7] - Net profit attributable to shareholders was ¥146,131,880.12, up 35.23% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥151,559,752.54, reflecting a 49.64% increase year-over-year[7] - Operating revenue for the first nine months of 2021 reached CNY 2,029,816,801.54, an increase of 36.41% compared to CNY 1,488,074,665.79 in the same period of 2020[14] - For the first three quarters of 2021, the company achieved a revenue of 2.03 billion RMB, representing a year-on-year growth of 36.41%[28] - The net profit attributable to shareholders for the same period was 361 million RMB, a year-on-year increase of 50.92%[28] - The overall gross margin for the first three quarters was 43.71%, up 2.16 percentage points from the previous year, while the net profit margin was 17.03%, an increase of 1.02 percentage points[28] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,875,751,349.57, a 30.66% increase from the end of the previous year[7] - The total number of common shareholders at the end of the reporting period is 22,247[21] - The total liabilities increased significantly, with accounts payable rising by 56.03% to CNY 460,222,415.93 due to increased procurement[14] - The company’s total current liabilities increased to RMB 1,667,183,933.67 from RMB 984,022,123.94 at the end of 2020[59] - Total liabilities amounted to $1,103,697,701.72, a decrease from $1,150,455,806.91, reflecting a reduction of $46,758,105.19[82] Cash Flow - The company recorded a net cash flow from operating activities of ¥250,627,959.49, which is a decrease of 26.35% year-over-year[7] - The company reported a net cash inflow from operating activities of CNY 1,760,701,968.10, a 32.92% increase from CNY 1,324,629,405.66 in the previous year[17] - The net cash flow from operating activities was $250.63 million, a decrease of 26.4% compared to $340.28 million in the previous period[73] - Cash inflow from financing activities was $522.35 million, down from $1.16 billion in the previous period[73] - The net cash flow from financing activities was $253.37 million, compared to $82.80 million in the previous period, indicating a substantial increase[73] Research and Development - R&D expenses increased by 95.81% to CNY 223,621,085.82, driven by an increase in R&D personnel and expansion of laboratory facilities[14] - The company invested 224 million RMB in R&D, accounting for 11.02% of total revenue, a 95.81% increase year-on-year[37] - Research and development expenses surged to ¥223,621,085.82, a significant increase from ¥114,200,845.95 in the previous period[66] Shareholder Information - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.72% of shares, totaling 80,112,365 shares[21] - The second-largest shareholder, Ju Nianfeng, holds 10.82% of shares, totaling 58,890,521 shares, with 50,480,087 shares pledged[21] - The company plans to repurchase and cancel 18,000 restricted shares from a departing incentive object, pending completion of procedures[26] - The total number of shares held by Ju Nianfeng is 50,480,087, which are subject to executive lock-up[24] Acquisitions and Investments - The company completed the acquisition of 70% of Hubei Yuyang Pharmaceutical Co., Ltd. for RMB 171.5 million, which was officially registered on September 16, 2021, and is now included in the consolidated financial statements[53] - Fixed assets increased by 25.37% to CNY 1,709,187,056.99, primarily due to the acquisition of 70% equity in Hubei Yuyang Pharmaceutical Co., Ltd.[14] - The company recognized goodwill of CNY 278,520,496.76, reflecting the acquisition of 70% equity in Hubei Yuyang Pharmaceutical Co., Ltd.[14] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[3] - The raw material CDMO business generated a revenue of 1.398 billion RMB, accounting for 69% of total revenue, with a year-on-year growth of 40%[38] - The gene and cell therapy CDMO business signed new orders worth approximately 105.11 million RMB, serving 11 clients and managing 16 projects[52] - The formulation CDMO business secured new orders amounting to 32.16 million RMB, serving 12 clients and managing 13 projects[52] Employee Information - The company expanded its global team to 3,610 employees, an increase of 975 from the end of 2020[28]